Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis for MYO stock:

Technical Analysis

The stock is currently trading at $6.11, showing a slight decline of -0.81% in the last regular trading session with minimal after-hours movement (+0.16%). The RSI of 49.05 indicates neutral momentum, neither overbought nor oversold.

Recent Developments

• Recent analyst coverage has been positive, with multiple firms maintaining bullish ratings :
  • Craig-Hallum: Strong Buy, PT raised to $9 (43.77% upside)
  • HC Wainwright: Strong Buy, PT $7.5 (58.9% upside)
  • Ascendiant Capital: Strong Buy, PT $9 (80.36% upside)

Key Support/Resistance Levels Based on Fibonacci analysis:

• Support levels: S1: $5.97, S2: $5.65, S3: $5.14
• Resistance levels: R1: $6.99, R2: $7.31, R3: $7.82
• Pivot point: $6.48

Recent News Impact The company recently filed a prospectus for a public offering, which will provide $17.3M in gross proceeds. These funds will be channeled into:

• Advertising spend
• Manufacturing capacity expansion
• Initial build of the O&P channel

Conclusion Given the strong analyst consensus, positive capital raise developments, and current technical setup, MYO appears to be in a favorable position for potential upside. The stock is trading near support levels with multiple price targets suggesting significant upward potential.

Based on the provided data and market analysis, here is the price prediction for MYO stock in 2025:

The stock price of MYO is expected to reach $8.50-9.00 by mid-2025, driven by strong revenue growth momentum and positive analyst sentiment. This projection is supported by Ascendiant Capital's recent price target increase from $8.50 to $9.00 while maintaining a Buy rating.

The stock has shown significant upward momentum since Q4 2024, rising from around $4 to current levels above $6, indicating growing market confidence. The company's preliminary Q2 revenue guidance came in above estimates, suggesting improving business fundamentals and execution.

The technical analysis shows the stock is currently consolidating around $6.10 after a strong rally, with next major resistance at $6.99 and support at $5.97 based on Fibonacci levels. The RSI at 49.05 indicates neutral momentum, while the positive MACD of 0.13 suggests potential continued upward movement.

The S1 support level for MYO Stock is $5.88 ,The R1 resistant level for MYO Stock is $6.64.

As of the end of day on 2025-01-24, the price of MYO Stock was $6.04.

The target price for MYO Stock according to analyst rating is 8.25, with the highest price target at 9.00 and the lowest at 7.50. Analysts have a Strong Buy rating on MYO Stock overall.

The market cap of MYO is $203.5M.

Based on the provided data, I'll analyze whether MYO is overvalued through multiple aspects.

Technical Analysis

The stock is currently trading at $6.11, showing a slight decline of 0.81% in regular market hours with a minor recovery of 0.16% in post-market trading.

Valuation Analysis

The Price-to-Sales (P/S) ratio has increased from 5.66 in Q1 2024 to 5.86 in Q3 2024, while the Price-to-Book (P/B) ratio has risen more significantly from 8.64 to 13.05 during the same period, suggesting an expanding valuation multiple.

Recent Development Myomo recently issued preliminary Q2 revenue guidance above estimates and saw a 20% increase in share price to $4.92, indicating strong business momentum. Additionally, Ascendiant Capital raised their price target from $8.5 to $9 while maintaining a Buy rating, reflecting analyst confidence in the company's growth prospects.

Conclusion At the current price of $6.11, MYO is not overvalued considering its strong revenue guidance, positive analyst outlook, and valuation metrics that are still within reasonable range for a growth company in the medical device sector.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.

Based on the provided data and technical analysis, here is the price prediction for MYO stock by 2030:

MYO stock is projected to reach $15-17 by 2030, driven by the company's expanding medical device business and growing adoption of its myoelectric orthosis technology. The recent analyst coverage from Ascendiant Capital raising the price target from $8.5 to $9 indicates positive market sentiment. The company's preliminary Q2 revenue guidance above estimates and 20% stock price increase demonstrates strong business momentum.

MYO has a total of 101 employees.